Dianthus Therapeutics (NASDAQ:DNTH) EVP Simrat Randhawa Sells 26,530 Shares of Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the completion of the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $362,480. The trade was a 86.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Simrat Randhawa also recently made the following trade(s):

• On Thursday, March 12th, Simrat Randhawa sold 33,830 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $81.48, for a total value of $2,756,468.40.

Dianthus Therapeutics Trading Down 8.8%

Shares of NASDAQ DNTH opened at $81.57 on Wednesday. Dianthus Therapeutics, Inc. has a twelve month low of $16.64 and a twelve month high of $96.50. The stock has a fifty day simple moving average of $86.99 and a 200-day simple moving average of $62.62. The stock has a market capitalization of $4.46 billion, a PE ratio of -19.75 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The business had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.40 million. On average, equities analysts predict that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on DNTH. Robert W. Baird lifted their price objective on Dianthus Therapeutics from $67.00 to $132.00 and gave the company an “outperform” rating in a research note on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Monday, April 20th. Wolfe Research assumed coverage on Dianthus Therapeutics in a research note on Thursday, April 9th. They issued an “outperform” rating and a $98.00 price objective for the company. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Stifel Nicolaus set a $120.00 target price on Dianthus Therapeutics in a report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $117.82.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. First Horizon Corp purchased a new position in Dianthus Therapeutics in the first quarter valued at $32,000. Caitong International Asset Management Co. Ltd purchased a new position in Dianthus Therapeutics in the fourth quarter valued at $40,000. Raymond James Financial Inc. purchased a new position in Dianthus Therapeutics in the second quarter valued at $27,000. Russell Investments Group Ltd. purchased a new position in Dianthus Therapeutics in the third quarter valued at $64,000. Finally, ABS Direct Equity Fund LLC purchased a new position in Dianthus Therapeutics in the first quarter valued at $179,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.